Table 1. Characteristics of clinical isolates from West and Central Africa (n = 184), by country.
| Resistance rate (%) or resistance statusa | |||||||||||
| Country of isolation | Number of isolates | ST or CC | Tic | Tzp | Caz | Fep | Atm | Imp | Amk | Tob | Cip |
| Senegal | |||||||||||
| Total | 78 | - | 7.7 | 1.3 | 1.3 | 1.3 | 0b | 0 | 1.3 | 5.1 | 3.8 |
| GES-9-producing isolate | 1 | 1469 | R | S | R | R | I | S | R | R | R |
| Central African Republic | |||||||||||
| Total | 28 | - | 25.0 | 10.7 | 7.1 | 0 | 0b | 0 | 0 | 7.1 | 7.1 |
| Ivory Coast | |||||||||||
| Total | 48 | - | 29.2 | 22.9 | 14.6 | 12.5 | 2.1b | 16.7 | 16.7 | 22.9 | 27.1 |
| VIM-2-producing isolates | 4 | 244 (n = 2), 233 (n = 2) | 100 | 100 | 100 | 100 | 100b | 100 | 100 | 100 | 100 |
| Nigeria | |||||||||||
| Total | 30 | - | 40.0 | 26.7 | 20.0 | 30.0 | 3.3b | 10 | 20 | 20 | 26.7 |
| GES-1-producing isolate | 1 | 235 | R | R | R | R | I | R | R | R | R |
| VIM-2-producing isolate | 1 | 233 | R | R | R | R | I | R | R | R | R |
a
Resistance rate or resistance status were defined according to the 2013 recommendations of the European Committee on Antimicrobial Susceptibility Testing (EUCAST, 2013 [13]). Tic: ticarcillin; Tzp: Pipercillin-tazobactam; Caz: Ceftazidime; Fep: Cefepime; Atm: Aztreonam; Imp: Imipenem; Amk: Amikacin; Tob: Tobramycin; Cip: Ciprofloxacin. Here, all non-susceptible isolates were considered as resistant.
b
Only isolates with an inhibition diameter around the disk of aztreonam (30 µg) <16 mm were considered as resistant.